15 Nov EULAR 2026: Falling IgG After Treatment May Help Track Response in Lyme Arthritis
Health Notice: This interview discusses a conference abstract from a retrospective, single-center study, and the findings are considered hypothesis-generating. It is for educational purposes only and is not medical advice. Anyone with joint swelling after a tick bite, or questions about Lyme disease testing or treatment, should speak with their own doctor.
Dr. Med. Anna Mihailova[/caption]
MedicalResearch.com Interview with:
Dr. med. Anna Mihailova
Orto Clinic
Riga, Latvia
EULAR 2026 Abstract AB0041:
Clinical and Serological Markers and Treatment Response in Lyme Arthritis (Puce S, Mihailova A)
Dr. LaMoreaux[/caption]
Brian LaMoreaux, MD, MS
Internist and Rheumatologist
Executive Medical Director, Amgen
MedicalResearch.com: What is the background for this study? How does KRYSTEXXA® (pegloticase) work in gout?
Response: Many other diseases in gout have well-defined definitions of remission, but gout has lagged behind on this. With systemic consequences of gout becoming more apparent, the concept of treating gout to remission is increasing important to improving patient care and preserving patient health.
Dr. Nowell[/caption]
W. Benjamin Nowell PhD
Director of Patient-Centered Research at Global Healthy Living Foundation
Columbia University in the City of New York
Dr. Connelly[/caption]
Stephen Connelly, PhD
Co-founder & Chief Scientific Officer
Kelly Gavigan[/caption]
Kelly Gavigan, MPH
Manager, Research and Data Science
Ruth Fernandez-Ruiz, MD
Post-Doctoral Fellow
Department of Rheumatology
NYU Langone Heath
MedicalResearch.com: What is the background for this study?
Response: Patients with systemic lupus erythematosus (SLE) represent a unique population in considering risk for COVID-19 with biologic, genetic, demographic, clinical and treatment issues at play. By the nature of their chronic inflammatory autoimmune condition, the presence of comorbidities, and regular use of immunosuppressants, these individuals would traditionally be considered at high risk of contracting SARS-CoV-2 and possibly having worse outcomes from the viral infection.
However, it might be speculated that inherently elevated type I Interferon, characteristic of the majority of patients with SLE, confers a protective effect as a first line anti-viral defense. Additionally, hydroxychloroquine, which was suggested as a potential therapeutic agent for COVID-19 early on, is used in most patients with SLE. Accordingly, we initiated this study to provide critical data needed to address the frequency and severity of COVID-19 in patients with SLE.